PMID- 21335363
OWN - NLM
STAT- MEDLINE
DCOM- 20120227
LR  - 20110322
IS  - 1479-6821 (Electronic)
IS  - 1351-0088 (Linking)
VI  - 18
IP  - 2
DP  - 2011 Apr
TI  - Expression of somatostatin receptors, dopamine D(2) receptors, noradrenaline 
      transporters, and vesicular monoamine transporters in 52 pheochromocytomas and 
      paragangliomas.
PG  - 287-300
LID - 10.1530/ERC-10-0175 [doi]
AB  - While somatostatin receptors (sst), through somatostatin-radiolabeled analogs, 
      are used, mainly in second line, in the diagnosis and treatment of 
      pheochromocytomas (PCC) and paragangliomas (PGL), the clinical significance of 
      dopamine receptor subtype 2 (D(2)) in PCC/PGL is unknown. Indeed, radiolabeled 
      dopamine (DA) analogs such as fluorine 18 ((18)F)-DA, used for positron emission 
      tomography in PCC localization, are mainly correlated to the presence of 
      noradrenaline transporter (NAT) and vesicular monoamine transporters (VMAT) but 
      not to D(2). The aim of this study was to quantitate D(2) and sst expression in 52 
      PCC/PGL and to compare it with that of 35 gastroenteropancreatic neuroendocrine 
      tumors (GEP-NETs). Quantitative RT-PCR of sst(1-3) and sst(5), D(2), NAT, VMAT1/2 was 
      performed in all tumors, while immunohistochemistry analysis of sst(2) and D(2) was 
      performed in seven tumors. D(2) mRNA was expressed in all PCC/PGL. Mean expression 
      was significantly higher in PCC/PGL than in GEP-NETs (4.8 vs 0.5 copy/copy 
      beta-glucuronidase (Gus)). sst(2) and sst(1) were expressed in most PCC/PGL, with 
      sst(2)-dominant expression (mean mRNA: 1.6 vs 0.4 copy/copy beta-Gus). sst(2) 
      expression level was similar to that of GEP-NETs, whereas sst(5) expression level 
      was significantly lower (0.12 vs 0.78 copy/copy beta-Gus). Our study evidenced 
      strong D(2) mRNA expression in PCC and for the first time in PGL. PCC/PGL express 
      sst(2) mRNA at levels similar to those of GEP-NETs. New drugs can target ssts and 
      D(2) more efficiently than current somatostatin analogs. Moreover, transporters 
      like NAT and VMAT1/2, could be co-targeted with sst, as a basis of new 
      radionuclide compounds in the imaging and treatment of these tumors.
FAU - Saveanu, Alexandru
AU  - Saveanu A
AD  - Laboratory of Biochemistry and Molecular Biology, Centre Hospitalo-Universitaire 
      Conception, 147 Boulevard Baille, 13385 Marseille, France.
FAU - Muresan, Mihaela
AU  - Muresan M
FAU - De Micco, Catherine
AU  - De Micco C
FAU - Taieb, David
AU  - Taieb D
FAU - Germanetti, Anne-Laure
AU  - Germanetti AL
FAU - Sebag, Frederic
AU  - Sebag F
FAU - Henry, Jean-Francois
AU  - Henry JF
FAU - Brunaud, Laurent
AU  - Brunaud L
FAU - Enjalbert, Alain
AU  - Enjalbert A
FAU - Weryha, Georges
AU  - Weryha G
FAU - Barlier, Anne
AU  - Barlier A
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110321
PL  - England
TA  - Endocr Relat Cancer
JT  - Endocrine-related cancer
JID - 9436481
RN  - 0 (Norepinephrine Plasma Membrane Transport Proteins)
RN  - 0 (RNA, Messenger)
RN  - 0 (Receptors, Dopamine D2)
RN  - 0 (Receptors, Somatostatin)
RN  - 0 (SLC18A1 protein, human)
RN  - 0 (SLC18A2 protein, human)
RN  - 0 (Vesicular Monoamine Transport Proteins)
SB  - IM
MH  - Adolescent
MH  - Adrenal Gland Neoplasms/metabolism
MH  - Adult
MH  - Aged
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Norepinephrine Plasma Membrane Transport Proteins/genetics/*metabolism
MH  - Pancreatic Neoplasms/metabolism
MH  - Paraganglioma/*metabolism
MH  - Pheochromocytoma/*metabolism
MH  - RNA, Messenger/metabolism
MH  - Real-Time Polymerase Chain Reaction
MH  - Receptors, Dopamine D2/genetics/*metabolism
MH  - Receptors, Somatostatin/genetics/*metabolism
MH  - Vesicular Monoamine Transport Proteins/genetics/*metabolism
MH  - Young Adult
EDAT- 2011/02/22 06:00
MHDA- 2012/03/01 06:00
CRDT- 2011/02/22 06:00
PHST- 2011/02/22 06:00 [entrez]
PHST- 2011/02/22 06:00 [pubmed]
PHST- 2012/03/01 06:00 [medline]
AID - ERC-10-0175 [pii]
AID - 10.1530/ERC-10-0175 [doi]
PST - epublish
SO  - Endocr Relat Cancer. 2011 Mar 21;18(2):287-300. doi: 10.1530/ERC-10-0175. Print 
      2011 Apr.